XML 25 R11.htm IDEA: XBRL DOCUMENT v3.24.0.1
REVENUE
 12 Months Ended
Dec. 31, 2023
Revenue from Contract with Customer [Abstract]  
REVENUE REVENUE
 The following table presents the Company’s revenues disaggregated by revenue source:
Year Ended December 31,
(In thousands)202320222021
Screening
Medicare Parts B & C$701,400 $545,458 $438,646 
Commercial992,244 743,238 569,944 
Other171,057 136,007 53,718 
Total Screening1,864,701 1,424,703 1,062,308 
Precision Oncology
Medicare Parts B & C$188,689 $197,327 $197,394 
Commercial181,318 177,518 180,177 
International153,277 117,738 109,913 
Other105,826 108,905 74,192 
Total Precision Oncology629,110 601,488 561,676 
COVID-19 Testing$5,955 $58,088 $143,103 
Total$2,499,766 $2,084,279 $1,767,087 
Screening revenue primarily includes laboratory service revenue from Cologuard and PreventionGenetics tests while Precision Oncology revenue includes laboratory service revenue from global Oncotype DX and therapy selection tests.
At each reporting period end, the Company conducts an analysis of the estimates used to calculate the transaction price to determine whether any new information available impacts those estimates made in prior reporting periods. The Company recognized revenue from a change in transaction price of $25.2 million and $20.3 million for the years ended December 31, 2023 and 2022, respectively. The Company recorded a downward adjustment to revenue from a change in transaction price of $11.8 million for the year ended December 31, 2021.
The Company’s deferred revenue, which is reported in other current liabilities in the Company’s consolidated balance sheets, was not significant as of December 31, 2023 and 2022.
Revenue recognized for the year ended December 31, 2023 and 2022, which was included in the deferred revenue balance at the beginning of the year